Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York.
Respir Care. 2020 Aug;65(8):1112-1119. doi: 10.4187/respcare.07550. Epub 2020 Jun 2.
We sought to longitudinally assess the efficacy of the patient-facing ASTHMAXcel mobile application in improving asthma knowledge and outcomes in adults with asthma.
ASTHMAXcel is a novel smartphone application consistent with the National Asthma Education and Prevention Program, Global Initiative for Asthma, and British Thoracic Society/Scottish Intercollegiate Guidelines Network guidelines. The intervention was provided for 1-time use at baseline only. The Asthma Knowledge Questionnaire (AKQ), the Asthma Control Test (ACT), and the mini-Asthma Quality of Life Questionnaire (mini-AQLQ) were administered at baseline and at 2, 4, and 6 months thereafter. Rates of asthma-related emergency department visits, hospitalizations, and prednisone use were also evaluated.
ACT scores increased significantly at 2, 4, and 6 months (mean scores: 15.1 vs 16.9, = .038; 15.1 vs 17.2, = .02; 15.1 vs 17.9, = .003) after baseline. There were significant increases in AKQ scores at 4 and 6 months (11.7 vs 12.6, = .02; 11.7 vs 13.1, = .005) and in mini-AQLQ scores at 6 months (55.5 vs 64.2, = .02). There were significant decreases in asthma-related emergency department visits at 6 months (0.6 vs 0, < .001) and in hospitalizations at 4 and 6 months (0.3 vs 0.1, = .02; 0.3 vs 0, = .002). Prednisone use decreased at 4 and 6 months (1.2 vs 0.6, = .01; 1.2 vs 0.3, < .001).
ASTHMAXcel contributes to improved asthma knowledge and outcomes and to decreased health care utilization. ASTHMAXcel is an inexpensive, scalable aid for out-patient asthma management.
我们旨在纵向评估面向患者的 ASTHMAXcel 移动应用程序在提高成年哮喘患者的哮喘知识和改善哮喘结局方面的效果。
ASTHMAXcel 是一款新型智能手机应用程序，符合美国国家哮喘教育和预防计划、全球哮喘倡议以及英国胸科协会/苏格兰校际指南网络指南的标准。该干预措施仅在基线时提供一次性使用。在基线以及之后的 2、4 和 6 个月时，我们使用哮喘知识问卷（AKQ）、哮喘控制测试（ACT）和迷你哮喘生活质量问卷（mini-AQLQ）进行评估。还评估了哮喘相关急诊就诊、住院和使用泼尼松的情况。
ACT 评分在 2、4 和 6 个月时显著升高（平均评分：15.1 比 16.9， =.038；15.1 比 17.2， =.02；15.1 比 17.9， =.003），高于基线。在 4 个月和 6 个月时，AKQ 评分显著升高（11.7 比 12.6， =.02；11.7 比 13.1， =.005），在 6 个月时 mini-AQLQ 评分显著升高（55.5 比 64.2， =.02）。在 6 个月时，哮喘相关急诊就诊显著减少（0.6 比 0， <.001），在 4 个月和 6 个月时住院显著减少（0.3 比 0.1， =.02；0.3 比 0， =.002）。在 4 个月和 6 个月时，泼尼松的使用量减少（1.2 比 0.6， =.01；1.2 比 0.3， <.001）。
ASTHMAXcel 有助于提高哮喘知识和改善哮喘结局，并减少医疗保健的利用。ASTHMAXcel 是一种经济实惠、可扩展的门诊哮喘管理辅助工具。
